| Weinsier et al. 1979 [21]United States of America | Cohort study | Age: NSCondition: NSSetting: General medical service | T0: Within 48 hours of admission (n = 144)T1: T0 + ≥ 2 weeks (based on LOS) (n = 44) | 52 years; 50% female | 1. Mid arm muscle circumference |
| Abad et al. 1986 [22]Spain | Retrospective cohort study | Age: NSCondition: Inflammatory bowel diseaseSetting: NS | T0: Admission (n = 47)T1: NS (n = 47) | 36 years; % female NS | 1. Mid arm muscle circumference |
| Sloan et al. 1992 [39]Canada | RCTCG: weekly placebo injectionTG: weekly nandrolone injection | Age: ≥ 65 yearsCondition: Hip fractureSetting: Orthopaedic service | T0: Within 48 hours of admission (CG n = 14, TG n = 15)T1: T0 + 1 week (CG n = 14, TG n = 15)T2: T0 + 2 weeks (CG n = 14, TG n = 15)T3: T0 + 3 weeks (CG n = 9, TG n = 14)T4: T0 + 4 weeks (CG n = 7, TG n = 12) | CG: 81 ± 6 years; 100% femaleTG: 83 ± 7 years; 100% female | 1. Mid arm muscle circumference2. Lean body mass (bioelectrical impedance)3. Handgrip strength |
| Potter et al. 1995 [23]United Kingdom | Cohort Study | Age: NSCondition: NSSetting: Geriatric Unit | T0: Admission (n = 69)T1: T0 + 2 weeks (n = 41)T2: T0 + 4 weeks (n = 20)T3: T0 + 6 weeks (n = 12) | 82.2 (range: 69–96) years; 65.2% female | 1. Mid arm muscle circumference2. Handgrip strength |
| Unosson et al. 1995 [24]Sweden | Cohort Study | Age: ≥ 70 yearsCondition: Hip fractureSetting: Orthopaedic department | T1: Pre-operativeT0: T0 + 2 weeks | 84.6 years; 84% female | 1. Mid arm muscle circumference2. Lean body mass (bioelectrical impedance) |
| AntonelliIncalzi et al.1996 [25]Italy | Cohort study | Age: ≥ 70 yearsCondition: NSSetting: Medicine and Geriatric wards | T0: Within 24 hours of admission (n = 302)T1: Discharge (n = 283)LOS: 22.9 ±17.2 | 78.8 ± 5.8 years; 53.3% female | 1. Mid arm muscle circumference |
| Saudny-Unterberger et al. 1997 [40]Canada | RCTCG: usual careTG: usual care + ‘aggressive oral nutritional support’; | Age: 40–85 yearsCondition: COPDSetting: Respiratory medicine service | T0: Admission(CG: n = 16, TG = 17)T1: T0 + 2 weeks(CG: n = 10, TG = 14) | CG: 69.4 ± 3.91 years; 30% femaleTG: 69.21 ± 2.21 years; 43% female | 1. Handgrip strength |
| Gupta et al. 2001 [26]United Kingdom | Cohort study | Age: ≥ 16 yearsCondition: severe pancreatitisSetting: NS | T0: Day 0 (n = 17)T1: Day 3 (n = 17)T2: Day 7 (n = 17) | Median: 60 (range: 38–89) years; 59% female | 1. Handgrip strength2. Mid arm muscle circumference |
| Humphreys et al. 2002 [50]Chile | Case control study | Age: NSCondition: NSSetting: Medical and surgical wards | T0: Admission (n = 50)T1: T0 + 15 days, or until discharge (n = 17)LOS: median 10 (range: 6–29) days | 55 ± 16 years; 48% female | 1. Handgrip strength |
| Spruit et al. 2003 [51]Belgium | Case control study | Age: NSCondition: COPDSetting: NS | T0: Day 2 (n = 34)T1: Day 7 (n = 25) | 69 ± 7 years; % female NS | 1. Knee extension strength |
| Mets et al. 2004 [41]Belgium | RCTCG: no study medicationTG1: NSAID during first 2 weeks of hospitalisationTG2: antipyretic treatment with acetaminophen during first 2 weeks of hospitalisation | Age: ≥ 70 yearsCondition: Acute infectionSetting: Geriatric ward | T0: Day 0–2 (CG: n = 14, TG1: n = 14, TG1: n = 15)T1: T0 + 7 days (CG: n = 14, TG1: n = 14, TG1: n = 15)T2: T0 + 14 days(CG: n = 14, TG1: n = 14, TG1: n = 15) | CG: 84 ± 6 years; 73% femaleTG1: 85 ± 6 years; 64% femaleTG2: 85 ± 6 years; 79% female | 1. Handgrip strength2. Handgrip fatigue resistance |
| Vermeeren et al. 2004 [42]Netherlands | RCTCG: placebo (flavoured water)TG: nutritional supplements | Age: NSCondition: COPDSetting: NS | T0: Day 1(CG: n = 24, TG: n = 23)T1: Day 3(CG: n = 24, TG: n = 23)T2: Day 7(CG: n = 24, TG: n = 23) | CG: 66 ± 8 years; 25% femaleTG: 65± 10 years; 64% female | 1. Handgrip strength (measured at T0 and T2)2. Knee extension strength (measured at T1 and T2)3. Lean body mass (bioelectrical impedance) |
| Bautmans et al. 2005 [27]Belgium | Cohort studyG1: raised inflammatory markersG2: normal inflammatory markers | Age: NSCondition: NSSetting: Geriatric ward | T0: Day 0(G1: n = 42, G2: n = 21)T1: T0 + 7 days(G1: n = 39, G2: n = 13)T2: T0 + 14 days(G1: n = 22, G2: n = 5) | G1: 85.8 ± 5.6 years; 67% femaleG2: 81.0 ± 5.6 years; 67% female | 1. Handgrip strength2. Handgrip fatigue resistance3. Shoulder extension4. Hip extension |
| Pitta et al. 2006 [28]BelgiumCohort | Cohort study | Age: NSCondition: COPDSetting: NS | T0: Day 2 (n = 24)T1: Day 7 (n = 18) | Median 69 (IQR: 60–78) years; 6% female | 1. Knee extension strength |
| Crul et al. 2007 [52]Belgium | Case control study | Age: NSCondition: COPDSetting: NS | T0: Day 2 (n = 14)T1: Day 7 (n = 14) | 68 ± 8 years; 7% female | 1. Knee extension strength |
| Crul et al. 2010 [53]Belgium | Case control study | Age: NSCondition: COPDSetting: NS | T0: Day 2 (n = 9)T1: Day 7 (n = 9) | 67 ± 8 years; 0% female | 1. Knee extension strength |
| Troosters et al. 2010 [43]Brazil | RCTCG: Usual careTG: Usual care + daily quadriceps resistance training for 7 days | Age: < 85 yearsCondition: COPDSetting: Respiratory Division | T0: Day 2 (n = 36)T1: Day 7 (n = 36) | CG: 69 ± 7 years; 26.3% femaleTG: 67 ± 8 years; 23.5% female | 1. Knee extension strength |
| Beyer et al. 2011 [44]Belgium | RCTCG: placeboTG: NSAID treatment | Age: ≥ 70 yearsCondition: raised inflammatory markerSetting: Acute Geriatric ward | T0: Day 0–2(CG: n = 15, TG: n = 15)T1: T0 + 7 days(CG: n = 14, TG: n = 14)T2: T0 + 14 days(CG: n = 13, TG: n = 10)T3: T0 + 21 days(CG: n = 11, TG: n = 8) | CG: median 82.5 (IQR: 79.5–86.5) years; 71.4% femaleTG: median 85.0 (IQR: 76.8–91.0) years; 64.3% female | 1. Lean body mass2. Handgrip strength3. Handgrip fatigue resistance4. Handgrip work |
| Wieboldt et al. 2012 [54]United Kingdom | Case control study | Age: adultCondition: Cystic FibrosisSetting: NS | T0: Day 0–1 (n = 17)T1: Discharge (n = 16)LOS 8.6 ± 3.6 days | 29.1 ± 8.6 years; 31% female | 1. Handgrip strength2. Knee extension strength |
| Arezzo di Trifiletti et al. 2013 [29]Italy | Cohort studyG1: with anorexiaG2: without anorexia | Age: NSCondition: NSSetting: Internal Medicine ward | T2: Day 0–1(G1: n = 11; G2: n = 94)T3: Discharge(G1: n = 11; G2: n = 94)Median LOS G1: 21.8 ± 19.2 days, G2: 13.8± 9.3 days | G1: 72.4 ± 12.9 years; 55% femaleG2: 65.4 ± 16.6 years; 26.6% female | 1. Handgrip strength |
| Bodilsen et al. 2013 [30]Denmark | Cohort study | Age: ≥ 65 yearsCondition: Acute medical illnessSetting: NS | T0: Day 0–1 (n = 33)T1: Discharge (n = 23)Median LOS: 7.5 (IQR: 4.25–11.0) | 82.7 ± 8.2 years; 46% female | 1. Handgrip strength2. Knee extension strength |
| Burtin et al. 2013 [55]Belgium | Case control study | Age: adultCondition: Cystic FibrosisSetting: NS | T0: Day 0 (n = 19)T1: Day 13 (n = 19) | 25 ± 6 years; 32% female | 1. Knee extension strengtha. Isometric maximum voluntary contractionb. Transcutaneous magnetic twitch stimulation |
| Mesquita et al. 2013 [31]Brazil | Cohort study | Age: NSCondition: COPDSetting: NS | T0: Day 0 (n = 19)T1: Discharge (n = 19)Median LOS: 4 (IQR: 3–5) | 67 ± 11 years; 36.8% female | 1. Knee extension strength |
| Borges et al. 2014 [45]Brazil | RCTCG: usual careTG: usual care + resistance training; | Age: NSCondition: COPDSetting: NS | T0: Day 1(CG: n = 25, TG: n = 21)T1: Discharge(CG: n = 14, TG: n = 15)LOS: CG: 9.6 ±3.2, TG: 8.0 ± 2.2 | CG: 67.8 ± 9.0 years; 28.6% femaleTG: 64.1 ± 12.5 years; 46.7% female | 1. Shoulder abduction strength2. Shoulder flexion strength3. Elbow flexion strength4. Knee extension strength5. Hip flexion strength6. Knee flexion strength |
| Martín-Salvador et al. 2015 [32]Spain | Cohort studyG1: <75 years of ageG2: ≥ 75 years of age | Age: As grouping categoriesCondition: PneumoniaSetting: NS | T0: “Admission”(G1: n = 68, G2: n = 48)T1: DischargeLOS: G1: 8.33 ± 3.9 days, G2: 8.05 ± 3.1 days | G1: range 35–72 years; 36.1% femaleG2: range 75–86 years; 54.2% female | 1. Handgrip strength2. Knee extension strength |
| José et al. 2016 [47]Brazil | RCTCG: usual care;TG: usual care + exercise programme | Age: > 18 yearsCondition: PneumoniaSetting: NS | T0: Day 0–1(CG: n = 17, TG: n = 32)T1: T0 + 9 days(CG: n = 17, TG: n = 32) | CG: 59 ± 18 years; 41% femaleTG: 51 ± 21 years; 47% female | 1. Elbow flexion strength2. Shoulder abduction strength3. Knee extension strength4. Knee flexion strength |
| Martín-Salvador et al. 2016 [48]Spain | RCTCG: usual careTG: usual care + one hour per day of physiotherapy treatment (breathing exercises, electrostimulation and resistance exercises) | Age: 65–90 yearsCondition: COPDSetting: Respiratory Units | T0: Day 0(CG: n = 20, TG: n = 24)T1: Discharge(CG: n = 20, TG: n = 24)LOS: CG: 9.49 ± 4.3, TG: 8.39 ± 3.3 | CG: 77.4 ± 5.2; 22% femaleTG: 78.82 (6.3); 16.8% female | 1. Knee extension strength |
| Rossi et al. 2016 [33]Italy | Cohort study | Age: ≥ 65 yearsCondition: NSSetting: Geriatrics Division | T0: Day 2T1: DischargeLOS: 10.54 ± 4.38 days | 80.83 ± 7.14 years; 37.1% female | 1. Handgrip strength |
| Torres-Sánchez et al. 2016 [46]Spain | RCTCG: usual care;TG: usual care + pulmonary rehabilitation (exercise based) | Age: NSCondition: COPDSetting: Respiratory ward | T0: “Admission”(CG: n = 25, TG: n = 24)T1: Discharge(CG: n = 25, TG: n = 24)Minimum LOS 7 days;LOS: CG: 8.8 ± 2 days, TG: 8.7 ± 2 days | CG: 73.70 ± 7.10 years; 9.1% femaleTG: 72.36 ± 8.91 years; 0% female | 1. Handgrip strength2. Knee extension strength |
| Jones et al. 2017 [34]United Kingdom | Cohort study | Age: ≥ 65Condition: NSSetting: Older Persons’ Unit | T0: Day 0–1 (n = 75)T1: Discharge (n = 75)Median LOS: 14 (IQR: 9–26) days | 84.77 ± 7.06 years; 64% female | 1. Handgrip strength |
| Karlsen et al. 2017 [35]Denmark | Cohort study | Age: ≥ 65 yearsCondition: NSSetting: Acute Geriatric Department | T0: Day 1–3 (n = 151)T1: Day 4–7 (n = 122)T2: Day 8–12 (n = 104) | 85.2 ± 7.2 years; 74% female | 1. Handgrip strength |
| Matsuo et al. 2017 [36]Japan | Cohort study | Age: ≥ 65 yearsCondition: NSSetting: Acute Care wards | T0: Day 0–1T1: DischargeMedian LOS 26 (IQR:16–40) days | 80.5 ± 7.9 years; 56.3% female | 1. Handgrip strength |
| Norheim et al. 2017 [37]Denmark | Cohort studyG1: Persistent inflammation during admissionG2: Inflammation at admission resolved | Age: NSCondition: Acute illness with raised inflammatory markersSetting: Geriatric ward | T0: “Admission”(G1: n = 138; G2: n = 76)T1: Discharge(G1: n = 138; G2: n = 76)LOS G1: median 11.0 (IQR: 8.0–15.0) days, G2: 8.0 (6.0–11.0) days | G1: median 87 (IQR: 81–91) years; 67% femaleG2: 85 (79–91) years; 68% female | 1. Handgrip strength |
| Torres-Sánchez, Valenza et al. 2017 [49]Spain | RCTCG: usual care;TG: usual care + seated pedalling programme | Age: ≥ 65 yearsCondition: COPDSetting: Respiratory ward | T0: “Admission”(CG: 29; TG: 29)T1: Discharge(CG: 29; TG: 29)LOS: CG: 10.38 ± 2.47,TG: 12.47 ± 1.9 | CG: 72.12 ± 8.19 years; 31% femaleTG: 75.65± 6.25 years; 24% female | 1. Knee extension strength |
| Torres-Sánchez, Cabera-Martos et al. 2017 [38]Spain | Cohort study | Age: > 40 yearsCondition: COPDSetting: Respiratory Care Unit | T0: Day 1 (n = 52)T1: Discharge (n = 52)LOS: 12.17 ± 5.17 days | 75.87 ± 6.14 years; 4.5% female | 1. Handgrip strength2. Knee extension strength |